- Home
- BEAM vs BBUC Comparison
BEAM vs BBUC Comparison
Compare BEAM & BBUC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- BBUC
- Stock Information
- Founded
- BEAM 2017
- BBUC 2022
- Country
- BEAM United States
- BBUC United States
- Employees
- BEAM N/A
- BBUC N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- BBUC
- Sector
- BEAM Health Care
- BBUC
- Exchange
- BEAM Nasdaq
- BBUC Nasdaq
- Market Cap
- BEAM 1.6B
- BBUC 2.2B
- IPO Year
- BEAM 2020
- BBUC N/A
- Fundamental
- Price
- BEAM $21.16
- BBUC $29.78
- Analyst Decision
- BEAM Strong Buy
- BBUC
- Analyst Count
- BEAM 11
- BBUC 0
- Target Price
- BEAM $48.90
- BBUC N/A
- AVG Volume (30 Days)
- BEAM 2.2M
- BBUC 106.6K
- Earning Date
- BEAM 08-05-2025
- BBUC 01-01-0001
- Dividend Yield
- BEAM N/A
- BBUC 0.85%
- EPS Growth
- BEAM N/A
- BBUC N/A
- EPS
- BEAM N/A
- BBUC N/A
- Revenue
- BEAM $63,578,000.00
- BBUC $8,309,000,000.00
- Revenue This Year
- BEAM N/A
- BBUC N/A
- Revenue Next Year
- BEAM $17.18
- BBUC N/A
- P/E Ratio
- BEAM N/A
- BBUC N/A
- Revenue Growth
- BEAM N/A
- BBUC 8.15
- 52 Week Low
- BEAM $13.53
- BBUC $19.84
- 52 Week High
- BEAM $35.25
- BBUC $32.47
- Technical
- Relative Strength Index (RSI)
- BEAM 65.49
- BBUC 49.45
- Support Level
- BEAM $19.02
- BBUC $29.62
- Resistance Level
- BEAM $22.51
- BBUC $30.51
- Average True Range (ATR)
- BEAM 1.15
- BBUC 0.83
- MACD
- BEAM 0.49
- BBUC -0.17
- Stochastic Oscillator
- BEAM 78.91
- BBUC 23.47
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About BBUC Brookfield Business Corporation Exchangeable Subordinate Voting Shares
Brookfield Business Corp is a company established as a vehicle that owns and operates certain services and industrial operations on a world-wide basis and an alternative vehicle for investors who prefer investing in its operations through a corporate structure. Its goal is to generate returns through long-term capital appreciation with a modest distribution yield.